Biocon Biologics
Subramanian Loganathan has a wealth of experience in the field of clinical development and medical science. Currently holding the title of Assoc Vice President and Head Medical Science for CDMA at Biocon Biologics, with previous leadership roles at Biocon, Daiichi Sankyo, Panacea Biotec Ltd, and Ranbaxy. With a MD in Physiology from Delhi University, Subramanian has worked on various clinical trials, bioequivalence projects, and research activities throughout their career.
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics